Anhui Anke Biotechnology (Group) Co., Ltd. (SZSE: 300009) has announced that its self-developed innovative drug, injection AK2405, has received acceptance of its clinical trial application from the National Medical Products Administration. The regulatory milestone marks a significant step forward in the company's oncology pipeline development.

Injection AK2405 is an antibody-drug conjugate (ADC) designed to target HER2, a well-established biomarker in cancer therapy. Preclinical studies have demonstrated that the candidate exhibits high specificity and potent anti-tumor activity, positioning it as a promising therapeutic option for patients with advanced malignancies.

The product is classified as a Class 1 therapeutic biological product, denoting its status as an innovative biologic, with the proposed indication covering advanced malignant solid tumors. This filing underscores the company's commitment to advancing cutting-edge treatments through its proprietary research and development efforts.